Raltitrexed
Raltitrexed is an antimetabolite agent used in chemotherapy, acting by inhibiting thymidylate synthase.
Product Specifications
CAS Number
112887-68-0
Product Name Alternative
ZD1694; D1694; ICI-D1694
UNSPSC
12352005
Hazard Statement
H300, H360
Target
Nucleoside Antimetabolite/Analog; Thymidylate Synthase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Raltitrexed.html
Concentration
10mM
Purity
99.51
Solubility
DMSO : ≥ 29 mg/mL
Smiles
CC(NC1=O)=NC2=C1C=C(CN(C)C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)S3)C=C2
Molecular Formula
C21H22N4O6S
Molecular Weight
458.49
Precautions
H300, H360
References & Citations
[1]Zhao H, et al. Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest. Oncol Res. 2016;23 (5) :237-48|[2]Dong Y, et al. Raltitrexed's effect on the development of neural tube defects in mice is associated with DNA damage, apoptosis, and proliferation. Mol Cell Biochem. 2015 Jan;398 (1-2) :223-31.|[3]Xue S, et al. Raltitrexed induces mitochondrial-mediated apoptosis in SGC7901 human gastric cancer cells. Mol Med Rep. 2014 Oct;10 (4) :1927-34.|[4]Waldman BC, et al. Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase. DNA Repair (Amst) . 2008 Oct 1;7 (10) :1624-35.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
